Genomic Health Inc. (GHDX)

71.51
NASDAQ : Health Technology
Prev Close 71.72
Day Low/High 69.69 / 72.07
52 Wk Low/High 50.77 / 92.18
Avg Volume 675.10K
Exchange NASDAQ
Shares Outstanding 37.29M
Market Cap 2.71B
EPS 0.70
P/E Ratio 54.76
Div & Yield N.A. (N.A)

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $30.89, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health (GHDX) Strong On High Relative Volume Today

Genomic Health (GHDX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Investors eyeing a purchase of Genomic Health Inc shares, but tentative about paying the going market price of $23.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $17.50 strike, which has a bid at the time of this writing of 55 cents.

Short Interest Increases 34.5% For GHDX

Short Interest Increases 34.5% For GHDX

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 563,388 share increase in total short interest for Genomic Health Inc , to 2,194,625, an increase of 34.54% since 01/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Relative Strength Alert For Genomic Health

Relative Strength Alert For Genomic Health

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Drops 44.5% For GHDX

Short Interest Drops 44.5% For GHDX

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 1,109,831 share decrease in total short interest for Genomic Health Inc , to 1,385,882, a decrease of 44.47% since 12/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Analysts' Actions -- Apple, American Eagle, General Motors, Under Armour and More

Analysts' Actions -- Apple, American Eagle, General Motors, Under Armour and More

Here are Monday's top research calls, including upgrades for Apple and General Motors, and downgrades for American Eagle and Under Armour.

Analysts' Actions -- Hyatt, Hess, Lockheed Martin, Smith & Wesson and More

Analysts' Actions -- Hyatt, Hess, Lockheed Martin, Smith & Wesson and More

Here are Wednesday's top research calls, including an upgrade for Lockheed Martin, and downgrades for Hyatt, Hess and Smith & Wesson.

Genomic Health (GHDX) Is Strong On High Volume Today

Genomic Health (GHDX) Is Strong On High Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

Strong On High Volume: Genomic Health (GHDX)

Strong On High Volume: Genomic Health (GHDX)

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

Commit To Purchase Genomic Health At $20, Earn 17.2% Annualized Using Options

Commit To Purchase Genomic Health At $20, Earn 17.2% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $21.31/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2016 put at the $20 strike, which has a bid at the time of this writing of $1.35.

Genomic Health (GHDX) Stock: Weak On High Volume Today

Genomic Health (GHDX) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health is Now Oversold (GHDX)

Genomic Health is Now Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Genomic Health At $22.50, Earn 8% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 8% Annualized Using Options

Investors eyeing a purchase of Genomic Health Inc shares, but cautious about paying the going market price of $26.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2016 put at the $22.50 strike, which has a bid at the time of this writing of $1.15.

Oversold Conditions For Genomic Health (GHDX)

Oversold Conditions For Genomic Health (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Drops 11.8% For GHDX

Short Interest Drops 11.8% For GHDX

The most recent short interest data has been released by the NASDAQ for the 01/15/2015 settlement date, which shows a 360,370 share decrease in total short interest for Genomic Health Inc , to 2,688,072, a decrease of 11.82% since 12/31/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 14.7% Higher For GHDX

Short Interest Moves 14.7% Higher For GHDX

The most recent short interest data has been released by the NASDAQ for the 11/28/2014 settlement date, which shows a 401,207 share increase in total short interest for Genomic Health Inc , to 3,130,583, an increase of 14.70% since 11/14/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Genomic Health (GHDX) Downgraded From Hold to Sell

Genomic Health (GHDX) Downgraded From Hold to Sell

Genomic Health (GHDX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GPIC, IXYS, LBTYB, MAC, MTSI, NVFY, SIMG, TROX, WMB Downgrades: ACM, AP, DATE, GEOS, GHDX, IKGH, ITI, MCEP, NKA, SCCO, TATT, TIPT, VTG Initiations: AMTX, BRX, CRTO, ESNT, MMI, QUNR, SCAI, VCYT, WUBA Read on to get TheStreet Quant Ratings' detailed report:

Genomic Health (GHDX) Upgraded From Sell to Hold

Genomic Health (GHDX) Upgraded From Sell to Hold

Genomic Health (GHDX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.

TheStreet Quant Rating: B+ (Buy)